down arrow

Novavax, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6700024010
USD
6.86
0.26 (3.94%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Verve Therapeutics, Inc.
Adaptive Biotechnologies Corp.
ADMA Biologics, Inc.
Novavax, Inc.
Inhibrx, Inc.
Dianthus Therapeutics, Inc.
Kymera Therapeutics, Inc.
Apogee Therapeutics, Inc.
Sana Biotechnology, Inc.
Cassava Sciences, Inc.
Axcella Health, Inc.
Why is Novavax, Inc. ?
1
Risky - Negative Book Value
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -28.22%, its profits have risen by 229.6% ; the PEG ratio of the company is 0
2
Below par performance in long term as well as near term
  • Along with generating -28.22% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Novavax, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Novavax, Inc.
-18.43%
-0.78
74.64%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
84.66%
EBIT Growth (5y)
43.28%
EBIT to Interest (avg)
-32.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
7.49
Sales to Capital Employed (avg)
-0.04
Tax Ratio
2.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.62%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
-16.01
EV to EBIT
1.52
EV to EBITDA
1.38
EV to Capital Employed
-1.00
EV to Sales
0.51
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

22What is working for the Company
NET SALES(HY)

Higher at USD 905.89 MM

NET PROFIT(HY)

Higher at USD 630.22 MM

RAW MATERIAL COST(Y)

Fallen by -3.01% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -1,048.67 %

DEBTORS TURNOVER RATIO(HY)

Highest at 8.35 times

-8What is not working for the Company
NET SALES(Q)

At USD 239.24 MM has Fallen at -23.75%

INTEREST(HY)

At USD 11.24 MM has Grown at 36.19%

Here's what is working for Novavax, Inc.
Net Profit
At USD 630.22 MM has Grown at 2,760.07%
Year on Year (YoY)
MOJO Watch
Net Profit trend is very positive

Net Profit (USD MM)

Net Profit
Higher at USD 630.22 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -1,048.67 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 8.35 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -3.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Novavax, Inc.
Net Sales
At USD 239.24 MM has Fallen at -23.75%
over average net sales of the previous four periods of USD 313.74 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Interest
At USD 11.24 MM has Grown at 36.19%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Non Operating Income
Highest at USD 0.11 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."